FENC
Fennec Pharmaceuticals Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$10.24Close
$349.8MMarket cap
$5.77 – $12.7852-week range
Nov 12, 2026Next report
Highlights
Strengths
- Leading the market RS 81 · stronger than 81% of stocks over 12 months
- Volume drying up last 10 days 35% under the 50-day average
Cautions
- Trend not confirmed 7 of 8 conditions · under the 50-day
- Results soon Nov 12, 2026, in 11 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
20%
1wk
up 1.6%
price change
1mo
down 3.8%
price change
12-month return
up 23%
market up 11% ·
its own up 10%
F-score
—
— Not assessed
Altman Z
2.73
Moderate risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
9.9×
price / book
Earnings yield
down 2.0%
EBIT / enterprise value
Cheaper than
16%
of the market · expensive
Revenue growth
down 6%
year on year
EPS growth
—
latest quarter
Sales growth
up 85%
latest quarter · +13 pts
ROE
down 27461%
return on equity
Free cash margin
down 28%
-$12.5M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Trade setup
ATR%
5.3%
$0.54 a day · 2×ATR $9.16
RS
81 / 99
vs the universe
Trend
7 / 8
under the 50-day
Relative volume
1.1×
vs 50-day average
Up/down volume
0.99
50 sessions
Implied move
—
no option chain · report Nov 12, 2026
Trend template · 7 of 8
- Price above the 50-day average: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 24.1% over the year, from 28m to 34m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Revenue shrinking Revenue fell 6.1% over the year, from $47.5M to $44.6M.
Last reported
Mar 24, 2026
Financials
- Gross
- Net -21820%
- Free cash -28%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $200,000 | — | $1.5M | $21.3M | $47.5M | $44.6M |
| Gross margin | — | — | 94% | 94% | — | — |
| Operating income | -$17.9M | -$17.2M | -$22.6M | -$12.8M | $2.6M | -$6.3M |
| Net income | -$18.1M | -$17.3M | -$23.7M | -$16.0B | -$436.0M | -$9.7B |
| Net margin | -9054% | — | -1545% | -75499% | -917% | -21820% |
| Earnings per share | -$763.96 | -$0.67 | -$0.90 | -$603.79 | -$15.97 | -$340.87 |
| Free cash flow | -$15.6M | -$14.2M | -$18.1M | -$17.1M | $27.0M | -$12.5M |
| Free cash margin | -7797% | — | -1176% | -81% | 57% | -28% |
| Cash | $30.3M | $21.1M | $23.8M | $13.3M | $26.6M | $36.8M |
| Long-term debt | — | $5.0M | $24.9M | $30.9M | $19.3M | — |
| Shareholders' equity | $29.1M | $15.8M | -$2.6M | -$11.6M | -$5.9M | $35.5M |
| Shares outstanding | 26m | 26.01m | 26.36m | 27.03m | 27.53m | 34.16m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 13, 2026 | Quarterly ↗ | Jun 30, 2026 | 44d |
| May 14, 2026 | Quarterly ↗ | Mar 31, 2026 | 44d |
| Mar 27, 2026 | Annual ↗ | Dec 31, 2025 | 86d |
| Nov 13, 2025 | Quarterly ↗ | Sep 30, 2025 | 44d |
| Aug 14, 2025 | Quarterly ↗ | Jun 30, 2025 | 45d |
| May 14, 2025 | Quarterly ↗ | Mar 31, 2025 | 44d |
| Mar 26, 2025 | Annual ↗ | Dec 31, 2024 | 85d |
| Nov 8, 2024 | Quarterly ↗ | Sep 30, 2024 | 39d |
| Aug 13, 2024 | Quarterly ↗ | Jun 30, 2024 | 44d |
| May 14, 2024 | Quarterly ↗ | Mar 31, 2024 | 44d |
| Mar 29, 2024 | Annual ↗ | Dec 31, 2023 | 89d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Sep 17, 2026 | Other events ↗ |
| Jun 10, 2026 | Shareholder vote ↗ |
| May 22, 2026 | Other events ↗ |
| May 18, 2026 | Director or officer change ↗ |
| Apr 28, 2026 | Director or officer change ↗ |
| Apr 22, 2026 | Other events ↗ |
| Apr 7, 2026 | Other events ↗ |
| Mar 24, 2026 | Results ↗ |
| Mar 16, 2026 | Other events ↗ |
| Mar 4, 2026 | Other events ↗ |
| Feb 20, 2026 | Other events ↗ |
| Dec 9, 2025 | Other events ↗ |